Download PDF
1
/
Pages
Previous article
Go back to website
Next article
If you have problems to see the content please click here
Other users also viewed these articles
Prevalence and risk factors of significant fibrosis in chronic hepatitis B patients with concurrent metabolic dysfunction-associated steatotic liver disease
Shan Hong; Yiwei Hao; Lei Sun; Ping Li; Junru Yang; Fuyang Zhang; Lingling He; Jing Zhang; Hongshan Wei;
10.1016/j.aohep.2024.101589
NAFLD is associated with less severe liver fibrosis in chronic hepatitis B: A multi-center, retrospective study
Renling Yao; Sufang Lu; Ruifei Xue; Jian Wang; Yuanwang Qiu; Yuxin Chen; Jiacheng Liu; Li Zhu; Jie Zhan; Suling Jiang; Shengxia Yin; Xin Tong; Weimao Ding; Jie Li; Chuanwu Zhu; Rui Huang; Chao Wu;
Ann Hepatol. 2024;29:
Oral 24-week probiotics supplementation did not decrease cardiovascular risk markers in patients with biopsy proven NASH: A double-blind placebo-controlled randomized study
Samantha Thifani Alrutz Barcelos; Amanda Souza Silva-Sperb; Helena Abadie Moraes; Larisse Longo; Bruna Concheski de Moura; Matheus Truccolo Michalczuk; Carolina Uribe-Cruz; Carlos Thadeu Schmidt Cerski; Themis Reverbel da Silveira; Valesca Dall'Alba; Mário Reis Álvares-da-Silva;
Ann Hepatol. 2023;28: